Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03658304 · ClinicalTrials.gov registry record · Phase 2
Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma
A Phase 2 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT03658304 is a Phase 2 study that has completed, run by University of Florida. The registered enrollment target is 29 participants.
The verdict
NCT03658304, a Phase 2 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
Results of previous studies suggest that the timing of intravesical mitomycin C administration may impact bladder tumor recurrence rate following radical nephroureterectomy. This is the first study of its kind to attempt to identify the importance of timing of mitomycin C administration relative to bladder tumor recurrence rate following radical nephroureterectomy.This study will investigate the one year bladder tumor recurrence rate in patients with urothelial carcinoma of the upper urinary tract following intraoperative administration of mitomycin C during a nephroureterectomy, as well as the time to bladder tumor recurrence in this patient population.
Interventions
- DRUG Mitomycin c
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2018-12-05 |
| Est. Completion | 2023-10-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03658304
The ClinicalTrials.gov registry entry for NCT03658304 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mitomycin c is the first listed.
NCT03658304 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03658304 about?
NCT03658304 is a clinical study titled "Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma". Results of previous studies suggest that the timing of intravesical mitomycin C administration may impact bladder tumor recurrence rate following radical nephroureterectomy. This is the first study of its kind to attempt to identify the importance of timing of mitomycin C administration relative to ...
What is the current status of trial NCT03658304?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2018-12-05. Estimated completion is 2023-10-17.
What interventions are being tested in trial NCT03658304?
The interventions under investigation include: Mitomycin c (DRUG).
Who is sponsoring clinical trial NCT03658304?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.